Key result
Chemotherapy and radiotherapy are associated with an increasing incidence of long-term cardiovascular diseases, including left ventricular dysfunction and chronic heart failure in cancer survivors.
This review highlights the importance of cardio-oncology teams in implementing primary prevention and early treatment strategies for left ventricular dysfunction and heart failure in cancer survivors.
Alerts clinicians to monitor cancer survivors for cardiotoxicity; leaves open optimal prevention strategies pending prospective studies.
Progress in cancer treatment has significantly improved survival of patients with cancer. However, the incidence of cardiovascular diseases such as left ventricular dysfunction (LVD) and chronic heart failure (HF) is increasing due to the long-term toxic effects of chemotherapy and radiotherapy. Cardio-oncology teams are necessary to ensure the implementation of primary prevention strategies and screening protocols for early recognition of LVD. Moreover, early administration of advanced treatment for HF is crucial to achieve left ventricular recovery. In this article we will focus on the prevalence of chronic HF among cancer survivors, the main risk factors of LVD and chronic HF, the prevention strategies and management based on the current evidence and, finally, the future perspectives in this field.
No takes yet. Share an insight, caveat, or question.
Montoro et al. (2015) conducted a review in Heart failure and left ventricular dysfunction in cancer survivors. Chemotherapy and radiotherapy are associated with an increasing incidence of long-term cardiovascular diseases, including left ventricular dysfunction and chronic heart failure in cancer survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: